title: Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
abstract: We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m(2) x 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily x 5 days, q28 on the first cycle, 200 mg/mq daily x 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.
authors.affiliation: Department of Radiotherapy, Catholic University of the Sacred Heart, Largo A. Gemelli, Rome, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Balducci
authors.forename: Giuseppe Roberto
authors.initials: GR
authors.lastname: D'Agostino
authors.forename: Stefania
authors.initials: S
authors.lastname: Manfrida
authors.forename: Filippo
authors.initials: F
authors.lastname: De Renzi
authors.forename: Gabriella
authors.initials: G
authors.lastname: Colicchio
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Apicella
authors.forename: Annunziato
authors.initials: A
authors.lastname: Mangiola
authors.forename: Alba
authors.initials: A
authors.lastname: Fiorentino
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Frascino
authors.forename: Giovanna
authors.initials: G
authors.lastname: Mantini
authors.forename: Berardino
authors.initials: B
authors.lastname: De Bari
authors.forename: Angelo
authors.initials: A
authors.lastname: Pompucci
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Valentini
authors.forename: Carmelo
authors.initials: C
authors.lastname: Anile
authors.forename: Numa
authors.initials: N
authors.lastname: Cellini
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020266:Radiotherapy, Conformal / Q000379:methods*; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: J Natl Cancer Inst. 1993 May 5;85(9):704-10
references.pmid: 8478956
references.citation: Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389-96
references.pmid: 2542193
references.citation: Rev Neurol (Paris). 1992;148(6-7):428-34
references.pmid: 1448662
references.citation: Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1175-84
references.pmid: 10613310
references.citation: Cancer. 1993 Apr 15;71(8):2585-97
references.pmid: 8453582
references.citation: Nat Clin Pract Oncol. 2008 Aug;5(8):476-86
references.pmid: 18542116
references.citation: Strahlenther Onkol. 2008 Nov;184(11):572-9
references.pmid: 19016015
references.citation: J Neurosurg. 2001 Aug;95(2):190-8
references.pmid: 11780887
references.citation: Cancer. 2004 Nov 1;101(9):2098-105
references.pmid: 15389472
references.citation: J Clin Neurosci. 2006 Jan;13(1):18-22
references.pmid: 16356721
references.citation: Cancer Res. 2001 Mar 1;61(5):1957-63
references.pmid: 11280752
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1485-91
references.pmid: 12697871
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: J Neurooncol. 2004 Mar-Apr;67(1-2):77-81
references.pmid: 15072451
references.citation: J Neurosurg. 1989 Jul;71(1):1-9
references.pmid: 2661738
references.citation: N Engl J Med. 2001 Jan 11;344(2):114-23
references.pmid: 11150363
references.citation: Anticancer Drugs. 1997 Jan;8(1):92-7
references.pmid: 9147618
references.citation: Cancer. 1983 May 15;51(10):1826-9
references.pmid: 6831348
references.citation: J Clin Oncol. 1998 Dec;16(12):3851-7
references.pmid: 9850030
references.citation: Radiother Oncol. 2002 Sep;64(3):259-73
references.pmid: 12242114
references.citation: Clin Oncol (R Coll Radiol). 2009 Feb;21(1):19-22
references.pmid: 18838255
references.citation: Anticancer Res. 2003 Nov-Dec;23(6D):5159-64
references.pmid: 14981983
references.citation: Strahlenther Onkol. 2005 Mar;181(3):157-63
references.pmid: 15756519
references.citation: Lancet. 2002 Mar 23;359(9311):1011-8
references.pmid: 11937180
references.citation: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92
references.pmid: 17967509
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):999-1005
references.pmid: 18258384
references.citation: Neurol Clin. 2007 Nov;25(4):975-1003, viii-ix
references.pmid: 17964023
references.citation: Cancer Treat Rep. 1983 Feb;67(2):121-32
references.pmid: 6337710
references.citation: Br J Cancer. 2000 Apr;82(8):1371-80
references.pmid: 10780513
references.citation: Br J Cancer. 2006 Nov 6;95(9):1155-60
references.pmid: 17024124
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Gynecol Oncol. 2000 Sep;78(3 Pt 1):324-8
references.pmid: 10985888
references.citation: Cancer. 1980 Apr 15;45(8):2220-4
references.pmid: 7370963